Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is frequently in the news as a global company focused on pet healthcare innovation, veterinary diagnostics, and software. News about IDEXX often highlights product launches, diagnostic advances, financial results, and corporate governance updates, reflecting its role in companion animal care, livestock and dairy health, and water safety.
Recent announcements include new diagnostic imaging and cancer testing capabilities. IDEXX has introduced the Vue DR50 Plus Digital Imaging System, described as its most advanced diagnostic imaging solution for veterinary practices, combining high-definition, AI-powered imaging with lower radiation doses compared with earlier IDEXX systems and other veterinary imaging solutions. The company has also reported expansions of its IDEXX Cancer Dx Panel and applications on the inVue Dx Cellular Analyzer, aimed at providing earlier insights and rapid, in-clinic answers for canine cancer cases.
Investors and veterinary professionals following IDXX news will also encounter quarterly earnings releases, where IDEXX discusses revenue growth, earnings per share, and performance across areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Additional news items cover topics like CEO succession planning, board appointments, and participation in investor conferences.
This news page aggregates these types of updates so readers can review IDEXX’s latest disclosures on diagnostics, software, AI-enabled tools, telemedicine services, and financial performance. For anyone tracking IDXX stock, veterinary sector developments, or advances in animal health diagnostics, this feed provides a centralized view of the company’s publicly reported developments over time.
IDEXX Laboratories (NASDAQ: IDXX) reported positive trends in the U.S. Companion Animal Market as of July 31, 2020. Same-store clinical visits rose by 6%, while total practice revenue increased by 10%. These metrics reflect continued growth in companion animal healthcare, signaling strong demand for IDEXX's veterinary diagnostics and software solutions. The insights were made available on IDEXX's investor relations website.
IDEXX Laboratories (NASDAQ: IDXX) has expanded its imaging portfolio with the introduction of the ImageVue® DR30 Digital Imaging System. This system enhances image contrast and sharpness while reducing radiation doses by 25% or more. Positioned as an affordable option, it targets veterinary practices upgrading from older systems, providing significant efficiency improvements with a 70% faster workflow. The launch reflects IDEXX's commitment to innovation in veterinary diagnostics, ensuring better care for pets and safety for veterinary staff.
IDEXX Laboratories (NASDAQ: IDXX) announced the launch of the ProCyte One Hematology Analyzer on August 12, 2020. This analyzer promises breakthrough workflow simplicity and delivers reference laboratory-quality results at the point of care. Currently available for pre-sale in North America and select European markets, volume shipping is expected in the first quarter of 2021. The ProCyte One features unique pay-per-run and auto-replenishment models, enhancing financial flexibility for veterinarians while simplifying the diagnostic process.
IDEXX Laboratories (NASDAQ: IDXX) will host its 2020 virtual Investor Day on August 13, 2020, from 10:00 am to 12:00 pm ET. This event features executive presentations and a Q&A session with the senior leadership team, including Jay Mazelsky, Brian McKeon, and others. A live webcast will be available at www.idexx.com/investors, and an archived replay will be accessible shortly after the event. As a leader in veterinary diagnostics and healthcare innovation, IDEXX serves customers in over 175 countries.
IDEXX Laboratories reports a 3% revenue increase to $638 million for Q2 2020, with 4% organic growth, bolstered by a 7% rise in Companion Animal Group (CAG) Diagnostics. EPS rose 20% to $1.72, reflecting effective cost control and operational efficiency. However, new CAG instrument placements and Water business revenues faced declines due to COVID-19 impacts. Notable growth in CAG diagnostics was observed, supported by improved clinical visit trends. The company has suspended full-year guidance amid ongoing pandemic uncertainty.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will release its second-quarter financial results for 2020 on July 31, 2020, before market opening. The company will hold an analyst conference call at 8:30 a.m. ET, accessible via a webcast on their website. A virtual Investor Day is scheduled for August 13, 2020, from 10:00 a.m. to 12:00 p.m. ET, with a replay available post-event. IDEXX, a leader in veterinary diagnostics, employs over 9,000 people and serves customers in over 175 countries.